Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

M.H.G. Langenberg, P.O. Witteveen, J.M. Roodhart, H.M.W. Verheul, M. Mergui-Roelvink, J. van der Sar, E. Brendel, N. Laferriere, J.H.M. Schellens, E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2187-2197
JournalClinical Cancer Research
Issue number7
Publication statusPublished - 2010

Cite this